SCHEMBL6959301

SCHEMBL6959301

CCCOC(=O)NC(=N)c1ccc(C(=O)Nc2ccc3c(c2)CCC(CC(=O)OCC)O3)cc1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 11/20 0.56
ITGA2B P08514 11/20 0.56
RAB9A P51151 6/20 0.39
NPC1 O15118 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 5/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6957424 0.95 ITGB3 (0.59) ITGB3ITGA2BRAB9ANPC1MEN1
SCHEMBL6954012 0.93 ITGB3 (0.59) ITGB3ITGA2BRAB9ANPC1MEN1
SCHEMBL8545462 0.92 ITGB3 (0.67) ITGB3ITGA2BRAB9ANPC1MEN1
SCHEMBL6959422 0.90 ITGB3 (0.47) ITGB3ITGA2BRAB9ANPC1MEN1
SCHEMBL6954243 0.88 ITGB3 (0.60) ITGB3ITGA2BRAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL6949257 0.87 ITGB3 (0.60) ITGB3ITGA2BRAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL6950239 0.87 ITGB3 (0.57) ITGB3ITGA2BRAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL7076499 0.86 ITGB3 (0.59) ITGB3ITGA2BRAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL6955140 0.85 ITGB3 (0.62) ITGB3ITGA2BRAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL6957966 0.85 ITGB3 (0.56) ITGB3ITGA2BRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130342-A1 Glycoprotein llb/llla antagonists FISHER MATTHEW J (US) 2003-07-10 US disclosed
EP-0804431-B9 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2003-01-02 EP disclosed
US-6448269-B1 SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS ELI LILLY AND COMPANY 2002-09-10 US disclosed
EP-0804431-B1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2002-07-24 EP disclosed
US-6020362-A ANTICOAGULANTS ELI LILLY AND COMPANY (US) 2000-02-01 US disclosed
US-5731324-A Glycoprotein IIb/IIIa antagonists ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
WO-1996022288-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130342-A1 Glycoprotein llb/llla antagonists SELL, SELPLG, LY96 ITGB3 653/4885ITGA2B 294/4885RAB9A 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.